spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

medmix Drug Delivery (Haselmeier™) and AARDEX® Group Join Forces to Improve Self-Administration of Injectable Drugs in Clinical Trials.

AARDEX Group




Liege, Belgium - November 3, 2022: medmix Drug Delivery (Haselmeier) and AARDEX Group announced today a collaboration, combining Haselmeier´s D-Flex™ Logbook with AARDEX Group’s Medication Adherence software and hardware ecosystem.



Clinical testing during new drug development is costly and time intensive for pharmaceutical and biotech companies. The need for solutions, helping them to shorten testing time and increase data quality are two of the main factors determining overall cost and success of newly developed drugs. As a result, the future of clinical trials is becoming more reliant on connected medical devices, collecting data at the point of care, reducing the need for costly patient visits and cumbersome manual data acquisition. Therefore, Haselmeier, a medmix Brand, and AARDEX Group have joined forces to tackle the challenge of managing patient adherence during clinical trials.

Haselmeier developed the D-Flex Logbook, a wireless connected drug delivery solution. Now this solution can be easily integrated into AARDEX Group’s adherence software, MEMS AS®. This electronic data capture system has been successfully utilized to collect patient adherence data from digitally enabled devices such as pillboxes and drug containers for over 20 years. The combination of the two systems allows researchers to understand and manage patient adherence in clinical trials testing self-injection therapies.

Given AARDEX Group’s and Haselmeier´s decades long experience in the pharma industry, the collaboration comes naturally, complementing one another’s offering in clinical testing. This evidence-based approach can make the difference between failed and successful clinical trials.
phone +32 4 374 86 30
web https://www.aardexgroup.com/
email TheLabs - Liege Science Park, 15/1, rue bois St Jean, 4102 Seraing Belgium
 
Print this page
Send to a friend
   
spacer
News and Press Releases

CluePoints Appoints Andy Cooper as New Chief Executive Officer

King of Prussia, PA – December 13, 2022: RBQM leader, CluePoints, has today announced Andy Cooper has been appointed as its new Chief Executive Officer. Cooper succeeds Co-Founder, Francois Torche, who is stepping back as CEO to focus his full attention on the strategic direction of CluePoints’ world-leading product portfolio.
More info >>


White Papers

Autoinjector testing made safe efficient and flexible

ZwickRoell

The autoinjector market is one of the fastest growing markets across almost all pharmaceutical applications. Studies expect a global market volume of approximately USD 2.5 billion by 2020, with pre-filled autoinjectors representing the largest market segment. There are a variety of tests that can be performed on autoinjectors, and these are well-demonstrated by the Zwick product portfolio. The Ulm-based company and specialist in testing systems offers a variety of testing systems that are already being successfully used by multiple pharmaceutical companies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement